Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Carl R. who wrote (2002)	1/10/2000 10:35:00 AM
From: out_of_the_loop	Read Replies (1) \| Respond to of 5582

Tremacamra basically proves the blockade or decoy against ICAM blocks the cycle of infection of rhinoviruses. It will, according to the company, never be produced, though. It is a bioengineered molecule and has been discussed on this thread before. I am off work today so I do not have the other references, so try this government sheet niaid.nih.gov Basically, they are age dependent so the percentages will vary among pediatric, adolescent and adult groups. The percentage of rhinovirus-caused colds varies from 30-65%, depending on who and what you read so I am not alarmed by the percentages in that reference. In any case, you get the idea of what viruses are the "players". Zicam will not prevent the cycle of infection/autoinfection if the ICAM is not the receptor mediating the cycle. It may help in the symptoms somewhat, but that has not been studied yet - I am stating that on the basis of people reporting their allergy symptoms being helped (being studdied now) and some of the mechanisms of inflammation may be affected by Zicam.

To: Carl R. who wrote (2002)	1/10/2000 11:04:00 AM
From: DanZ	Read Replies (1) \| Respond to of 5582

Carl, Tremacamra was discussed in detail on SI around the time that the JAMA article was published. I don't have specific message numbers but if you are interested in the discussion, you might try scanning this thread and the Dog Pound thread around that date. Howard wrote some very good material at that time. The company that was working on tremacamra scrapped the project just after their article was published in JAMA. I believe that this had more to do with development and marketing issues than the science behind it. The following link contains information on picornaviruses, of which rhinoviruses are a member. It may not answer your question about all viruses that cause the common cold, but it is interesting information. www-micro.msb.le.ac.uk I agree with your comments concerning the probability that Zicam prevents colds that are caused by the rhinovirus. I previously wrote about this subject somewhere on SI and Yahoo. If one accepts the theoretical mechanism of action, that Zicam interferes in the auto-innoculation process, then it follows that Zicam probably also prevents the common cold. The reason is because the auto-innoculation process is nothing more than additional iterations of the initial infection process. Best regards, Dan